Our Services
Clinical Trial Management Services
Central Laboratory Services
Clinical Pharmacology
Scintigraphy
Pharmacovigilance
Regulatory Affairs
Clinical & Medical Writing
Clinical Trial Management Services
Phase I
Phase II
Phase III
Site Management & Monitoring
IMP Management
Biometric Services
We worked with Faron Pharmaceuticals on this trial, a multicentre first-in-human phase I/II study. It assessed the tolerability, safety and preliminary efficacy of FP-1305 in patients with advanced cancers including immunotherapy-refractory melanoma, cholangiocarcinoma, hepatocellular carcinoma, ovarian cancer, colorectal (CRC), and pancreatic ductal adenocarcinoma.
